An FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's...
Friday, January 11, 5:52 AM ETAn FDA advisory committee yesterday voted 10 to 5 to recommend approving Johnson & Johnson's (JNJ) canagliflozin treatment for Type 2 diabetes, although several of the panelists expressed concerns about its cardiovascular risks and its use for patients with moderate kidney disease. If authorized, analysts have forecast that canagliflozin could generate annual sales of $667M by 2016.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles